Print

Takeda Pharmaceutical Co. Ltd. (TKPYY) and Affymax, Inc. (AFFY) Announce Supply Agreement for OMONTYS® (Peginesatide) Injection With DSI Renal, Inc.  
1/7/2013 10:07:12 AM

DEERFIELD, Ill. & PALO ALTO, Calif.--(BUSINESS WIRE)--Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) and Affymax, Inc. (Nasdaq: AFFY) today announced that Takeda Pharmaceuticals America, Inc. (TPA) has entered into a supply agreement for sourcing and supply of OMONTYS® (peginesatide) Injection with DSI Renal, one of the largest dialysis providers in the United States (U.S.). OMONTYS is the only once-monthly erythropoiesis-stimulating agent (ESA) for anemia available to the adult dialysis patient population with chronic kidney disease (CKD) in the U.S.
//-->